Advertisement

Oxazolidinediones

  • R. Kretzschmar
  • H. J. Teschendorf
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 74)

Abstract

Until the introduction of succinimides for therapeutic use in 1960, oxazolidinediones were the drugs of choice in the treatment of petit mal epilepsy. They had been used since 1946. Now the oxazolidinediones are merely of historical interest since their clinical tolerance is unequivocally inferior to that of the succinimides. Nevertheless, their pharmacology deserves detailed consideration since they were the first relatively selective petit mal antiepileptics on which intensive experimental investigations of the type and mechanisms of action were carried out. Several reviews have dealt with oxazolidinediones (Woodbury et al. 1972, 1982; Withrow 1980). For structure-activity relationship see Chap. 9, this volume.

Keywords

Antiepileptic Drug Anticonvulsant Effect Audiogenic Seizure Maximal Electroshock Anticonvulsant Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adamska-Dyniewska H, Czernek Z, Goch JH, Rosiek S (1970) Anticonvulsants in treatment of ouabain-induced ectopic heart activity in cats. Pol Tyg Lek 25: 1205–1207PubMedGoogle Scholar
  2. Ahmad A, Dhawan BN (1969) Metrazol test for rapid screening of anticonvulsants. Jpn J Pharmacol 19: 472–474PubMedCrossRefGoogle Scholar
  3. Albertson TE, Peterson SL, Stark LG (1980) Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology 19: 643–652PubMedCrossRefGoogle Scholar
  4. Ashton D, Wauquier A (1979) Behavioral analysis of the effects of 15 anticonvulsants in the amygdaloid kindled rat. Psychopharmacology 65: 7–13PubMedCrossRefGoogle Scholar
  5. Bastian JW (1961) Classification of CNS drugs by a mouse screening battery. Arch Int Pharmacodyn Ther 133: 347–364PubMedGoogle Scholar
  6. Baxter MG, Miller A A, Webster RA (1973) Some studies on the convulsant action of folic acid. Br J Pharmacol 48: 350–351Google Scholar
  7. Bianchi C., Beani L, Bertelli A (1975) Effects of some anti-epileptic drugs on brain acetylcholine. Neuropharmacology 14: 327–332PubMedCrossRefGoogle Scholar
  8. Bircher R, Kanai T, Wang SC (1963) Action of anticonvulsants (pentobarbital, trimethadione and 3-methyl-5,5-phenylethyl hydantoin) on the EEG, ECG and blood pressure changes induced by pentylenetetrazol, picrotoxin and deslanoside in dogs. Arch Int Pharmacodyn Ther 141: 357–376Google Scholar
  9. Bonnevaux De SC, Diez Altares MC, Carrillo L (1968) Autonomic response to pentamethylenetetrazol following trimethadione and benzodiazepines administration. Arch Int Pharmacodyn Ther 173: 34–43PubMedGoogle Scholar
  10. Bonnycastle DD, Giarman NJ, Paasonen MK (1957) Anticonvulsant compounds and 5-hydroxy-tryptamine in rat brain. Br J Pharmacol 12: 228–231Google Scholar
  11. Booker HE (1982) Trimethadione, toxicity. In: Woodbury DM, Penry JU, Pippenger CE (eds) Antiepileptic drugs. Raven, New York, pp 701–703Google Scholar
  12. Brauer RW, Mansfield WM, Beaver RW, Gillen HW (1979) Stages in development of high-pressure neurological syndrome in the mouse. J Appl Physiol 46: 756–765PubMedGoogle Scholar
  13. Brown NA, Shull G, Fabro S (1979) Assessment of the teratogenic potential of trimethadione in the CD-I mouse. Toxicol Appl Pharmacol 51: 59–71PubMedCrossRefGoogle Scholar
  14. Brown NA, Kao J, Fabro S (1980) Teratogenic potential of valproic acid. Lancet 1: 660–661PubMedCrossRefGoogle Scholar
  15. Brown WC, Schiffman DO, Swinyard EA, Goodman LS (1953) Comparative assay of antiepileptic drugs by “psychomotor” seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 107: 273–283PubMedGoogle Scholar
  16. Bulger WH, Wells PR, Roche EB (1976) Pharmacological assessment of 3-tert-butylsyd-none. J Pharm Sci 65: 109–111PubMedCrossRefGoogle Scholar
  17. Butler TC (1953) Quantitative studies of the demethylation of trimethadione (tridione). J Pharmacol Exp Ther 108: 11–17PubMedGoogle Scholar
  18. Butler TC (1955 a) Metabolic demethylation of 3,5-dimethyl-5-ethyl 2,4-oxazolidinedione (paramethadione, paradione). J Pharmacol Exp Ther 113:178–185Google Scholar
  19. Butler TC (1956 b) The effects of N-methylation in 5,5-disubstituted derivatives of barbituric acid, hydantoin, and 2,4-oxazolidinedione. J Am Pharm Assoc Sci Ed 44:367–370Google Scholar
  20. Butler TC, Waddell WJ (1954) The role of the liver in the demethylation on N-methyl derivatives of hydantoin and of 2,4-oxazolidinedione. J Pharmacol Exp Ther 110: 241–243PubMedGoogle Scholar
  21. Butler TC, Walddell WJ (1955) A pharmacological comparison of the optical isomers of 5-ethyl-5-methyl-2,4-oxazolidinedione and of 3,5-dimethyl-5-ethyl-2,4-oxazolidinedione (paramethadione, paradione). J Pharmacol Exp Ther 113: 238–240PubMedGoogle Scholar
  22. Butler TC, Waddell WJ (1957) Metabolic deethylation of 5,5-dimethyl-3-ethyl-2,4 oxazolidinedione ( Dimedion ). Arch int Pharmacodyn Ther 111: 308–313Google Scholar
  23. Butler TC, Waddell WJ (1958) N–Methylated derivatives of barbituric acid, hydantoin and oxazolidinedione used in the treatment of epilepsy. Neurology (Minneap.) 8: 106–112Google Scholar
  24. Butler TC, Mahaffee D, Mahaffee C (1952) Metabolic demethylation of 3,5,5-trimethyl-2,4-oxazolidinedione (trimethadione, Tridione ). Proc Soc Exp Biol Med 81: 450–452Google Scholar
  25. Butler TC, Waddell WJ, Poole DT (1965) Demethylation of trimethadione and metharbital by rat liver microsomal enzymes: substrate concentration-yield relationships and competition between substrates. Biochem Pharmacol 14: 937–942PubMedCrossRefGoogle Scholar
  26. Buttar HD, Dupuis I, Khera KS (1976) Fetotoxicity of trimethadione and paramethadione in rats Toxicol Appl Pharmacol 37: 126Google Scholar
  27. Buttar HS, Dupuis I, Khera KS (1978) Dimethadione-induced fetotoxicity in rats Toxicology 9: 155–164Google Scholar
  28. Cahen R, Boucard M, Faurre L, Vedel Y (1971) Effet de la 5,5-dimethyl 2-4 oxazolidinedione sur le comportement d’anxiété et d’aggression chez l’animal de laboratoire. C R Soc Biol (Paris) 165: 1035–1040Google Scholar
  29. Chamberlin HR, Waddell WJ, Butler TC (1965) A study of the product of demethylation of trimethadione in the control of petit mal epilepsy. Neurology 15: 449–454PubMedGoogle Scholar
  30. Chen G, Ensor CR (1950) Evaluation of antiepileptic drugs. Arch Neurol Psychiatry 63: 56–60PubMedGoogle Scholar
  31. Chen G, Portman R (1952) Titration of central-nervous-system depression. AM A Arch Neurol Psychiatry 68: 498–505Google Scholar
  32. Chen G, Ensor CH R, Clarke IG (1951) Central nervous action of hydantoins, oxazolidinediones and thiazolidones. AMA Arch Neurol Psychiatry 66: 329–337PubMedGoogle Scholar
  33. Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA (1979) The influence of cannabidiol and Δ9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 20: 365–375PubMedCrossRefGoogle Scholar
  34. Clincke G, Wauquier A (1979) Metrazol-produced impairment of passive avoidance retention specifically antagonized by anti-petit mal drugs. Psychopharmacology 66: 243–246PubMedCrossRefGoogle Scholar
  35. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 19: 317–366PubMedGoogle Scholar
  36. Consroe P, Wolkin A (1977) Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 201: 26–32PubMedGoogle Scholar
  37. Consroe P, Picchioni A, Chin L (1979) Audiogenic seizure susceptible rats. Fed Proc 38: 2411–2416PubMedGoogle Scholar
  38. Craig CR, Chiu P, Colasanti BK (1976) Effects of diphenylhydantoin and trimethadione on seizure activity during cobalt experimental epilepsy in the rat. Neuropharmacology 15: 485–489PubMedCrossRefGoogle Scholar
  39. Delgado JMR, Mihailovic L (1956) Use of intracerebral electrodes to evaluate drugs that act on the central nervous system. Ann NY Acad Sci 64: 644–666PubMedCrossRefGoogle Scholar
  40. Desmedt LKC, Niemegeers CJE, Lewi PJ, Janssen PAJ (1976) Antagonism of maximal Metrazol seizures in rats and its relevance to an experimental classification of antiepileptic drugs. Arzneimittelforsch 26: 1592–1603PubMedGoogle Scholar
  41. Diaz PM (1974) Interaction of pentylenetetrazol and trimethadione on the metabolism of serotonin in brain and its relation to the anticonvulsant action of trimethadione. Neuropharmacology 13: 615–621PubMedCrossRefGoogle Scholar
  42. Dressier WE, Rossi GV, Orzechowski RF (1972) Effect of several anticonvulsant drugs and procainamide against ouabain-induced cardiac arrhythmias in rabbits. J Pharm Sci 61: 133–134CrossRefGoogle Scholar
  43. Elazar Z, Blum B (1971) Effect of drugs on interictal spikes and afterdischarges in experimental epilepsy. Arch Int Pharmacodyn Ther 189: 310–318PubMedGoogle Scholar
  44. Endröczi E, Fekete T (1967) Amino acid composition of the ammon’s horn and the effect of anticonvulsant drugs. Acta Physiol Hung 32: 389–398Google Scholar
  45. Erwin VG, Deitrich RA (1973) Inhibition of bovine brain aldehyde reductase by anticonvulsant compounds in vitro. Biochem Pharmacol 22:2615–2624 Everett GM, Richards RK (1944) Comparative anticonvulsants action of 3,5,5-trimethyl-oxazolidine-2,4-dione (tridione), dilantin and phenobarbital. J Pharmacol Exp Ther 81: 402–407Google Scholar
  46. Faingold CL, Berry CA (1973 a) Anticonvulsant modification of tripelennamine effects on the electrographic activity of the cat brain. Neuropharmacology 12: 383–390Google Scholar
  47. Faingold CL, Berry CA (1973 b) Quantitative evaluation of the pentylenetetrazol-anticonvulsant interaction on the EEG of the cat. Eur J Pharmacol 24: 381–388Google Scholar
  48. Ferngren H (1968) Further studies on chemically induced seizures and their antagonism by anticonvulsants during postnatal development in the mouse. Acta Pharmacol Toxicol 26: 177–188CrossRefGoogle Scholar
  49. Ferngren H, Paalzow L (1967) Studies on electrically induced seizures and their antagonism by anticonvulsants during neonatal development in the mouse. Acta Pharmacol Toxicol 25 (Suppl 4): 60CrossRefGoogle Scholar
  50. Ferngren H, Paalzow L (1969) High frequency electro-shock seizures and their antagonism during postnatal development in the mouse. II. Effects of phenobarbital sodium, mephobarbital, trimethadione, dimethadione, ethosuximide and acetazolamide. Acta Pharmacol Toxicol 27: 249–261 (1969)Google Scholar
  51. Ferrari RA, Arnold A (1961) The effect of central nervous system agents on rat-brain γ-aminobutyric acid level. Biochim Biophys Acta 52: 361–367PubMedCrossRefGoogle Scholar
  52. Forda O, McIlwain H (1953) Anticonvulsants on electrically stimulated metabolism of separated mammalian cerebral cortex. Br J Pharmacol 8: 225–229Google Scholar
  53. Frey HH (1964) Note on the interactions of amphetamine with anticonvulsant drugs. Acta Pharmacol Toxicol 21: 290–298CrossRefGoogle Scholar
  54. Frey HH (1969) Determination of the anticonvulsant potency of unmetabolized trimethadione. Acta Pharmacol Toxicol 27: 295–300CrossRefGoogle Scholar
  55. Frey HH, Kretschmer B-H (1971) Anticonvulsant effect of trimethadione in mice during continued treatment via the drinking water. Arch Int Pharmacodyn Ther 193: 181–190PubMedGoogle Scholar
  56. Frey HH, Schulz R (1970) Time course of the demethylation of trimethadione. Acta Pharmacol Toxicol 28: 477–483CrossRefGoogle Scholar
  57. Gallagher BB (1972) Trimethadione and other oxazolidinediones: toxicity. In: Woodbury DM, Penry JK, Schmidt P (eds) Antiepileptic drugs. Raven, New York, pp 409–411Google Scholar
  58. Gandhi IC, Jindal MN, Patel VK (1976) Mechanism of neuromuscular blockade with some antiepileptic drugs. Arzneimittelforsch 26: 258–261PubMedGoogle Scholar
  59. Gardner CR, Webster RA (1973) The effect of some anticonvulsant drugs on leptazol and bicuculline induced acetylcholine efflux from rat cerebral cortex. Br J Pharmacol 47: 652Google Scholar
  60. Gardner CR, Webster RA (1977) Convulsant-anticonvulsant interactions on seizure activity and cortical acetylcholine release. Eur J Pharmacol 42: 247–256PubMedCrossRefGoogle Scholar
  61. Gilbert JC, Wyllie MG (1976) Effects of anticonvulsant and convulsant drugs on the ATP-ase activities of synaptosomes and their components. Br J Pharmacol 56: 49–57PubMedGoogle Scholar
  62. Gilbert JC, Ortiz WR, Millichap JG (1966) The effects of anticonvulsant drugs on the permeability of brain cells to D-xylose. J Neurochem 13: 247–255PubMedCrossRefGoogle Scholar
  63. Go K, Tsurumi K, Fujimura H ( 1978 a) Anti-convulsant effect of phthalazino-2,3-b-phthalazine-5(14H), 12(7H)-dione (L-5418). I. Behavioral effect. Jpn J Pharmacol 28: 1–12Google Scholar
  64. Go K, Tsurumi K, Fujimura H (1978 b) Anti-convulsant effect of phthalazino-[2,3b]-phthalazine-5 (14H), 12 (7H)-dione (L-5418). II. Electroencephalographic study. Jpn J Pharmacol 28:93–104 Godschalk M, Dzoljic MR, Bonta IL (1976) Antagonism of gamma-hydroxybutyrate-induced hypersynchronization in the ECoG of the rat by anti-petit mal drugs. Neurosci Lett 3: 145–150Google Scholar
  65. Gogerty JH, Gunn CG (1964) Effects of various centrally acting agents on penicillin-induced temporal lobe seizures in cats. Fed Proc 23: 349Google Scholar
  66. Goodman L, Manuel C (1945) The anticonvulsant properties of dimethyl-TV-methyl barbituric acid and 3,5,5-trimethyloxazolidine-2,4-dione (tridione). Fed Proc 4: 119Google Scholar
  67. Goodman LS, Toman EP (1945) Experimental indices for comparing the efficacy of compounds with anticonvulsant and antiepileptic properties. Fed Proc 4: 120Google Scholar
  68. Goodman LS, Toman JEP, Swinyard EA (1946 a) The anticonvulsant properties of tridione. Am J Med 1: 213–228Google Scholar
  69. Goodman LS, Swinyard EA, Toman JEP (1946 b) Further studies on the anticonvulsant properties or tridione (3,5,5-trimethyloxazolidinedione). Fed Proc 5: 179–180Google Scholar
  70. Goodman LS, Singh Grewal M, Brown WC, Swinyard EA (1953) Comparison of maximal seizures evoked by pentylenetetrazol ( Metrazol) and electroshock in mice, and their modification by anticonvulsants. J Pharmacol Exp Ther 108: 168–176Google Scholar
  71. Gordon SR (1981) Anticonvulsants found to have teratogenic potential. JAMA 245: 36CrossRefGoogle Scholar
  72. Granick S (1966) The induction in vitro of the synthesis of δ-aminolevulinic acid synthetase in chemical prophyria: a response to certain drugs, sex hormones and foreign chemicals. J Biol Chem 241: 1359–1375PubMedGoogle Scholar
  73. Greengard O, McIlwain H (1955) Anticonvulsants and the metabolism of separated mammalian cerebral tissues. Biochem J 61: 61–68PubMedGoogle Scholar
  74. Gross GJ, Woodbury DM (1972) Effects of pentylenetetrazol on ion transport in the isolated toad bladder. J Pharmacol Exp Ther 181: 257–272PubMedGoogle Scholar
  75. Himwich HE, Essig CF, Hampson JL, Bales PD, Freedman AM (1950) Effect of trimethadione (tridione) and other drugs on convulsions caused by di-isopropyl fluorophosphate ( DFP ). Am J Psychiatry 106: 816–820Google Scholar
  76. Hori M, Ito T, Yoshida K, Shimizu, M (1979) Effect of anticonvulsants in spiking activity induced by cortical freezing in cats. Epilepsia 20: 25–36PubMedCrossRefGoogle Scholar
  77. Iorio LC, Ryan EA, Gogerty JH (1973) Anticonvulsant testing with a new analeptic convulsant: N-sulfamoyl-hexahydroazepine (Sah 41–178). Arch Int Pharmacodyn Ther 206: 282–287PubMedGoogle Scholar
  78. Ito T, Hori M, Yoshida K, Shimizu M (1977 a) Effect of anticonvulsants on seizures developing in the course of daily administration of pentetrazol to rats. Eur J Pharmacol 45: 165–172Google Scholar
  79. Ito T, Hori M, Yoshida K, Shimizu M (1977 b) Studies on freezing-induced experimental epilepsy: II. Effect of anticonvulsants on secondary generalized seizures in cats. Jpn J Pharmacol 27 (Suppl):35Google Scholar
  80. Ito T, Hori M, Yoshida K, Shimizu M (1979) Effect of anticonvulsants on experimental cortical epilepsy induced by tungstic acid gel in rats. Arch Int Pharmacodyn Ther 241: 287–299PubMedGoogle Scholar
  81. Johnson DD, Crichlow EC, Crawford RD (1974) Epileptiform seizures in domestic fowl IV. The effects of anticonvulsant drugs. Can J Physiol Pharmacol 52: 991–994Google Scholar
  82. Joy RM (1973) Electrical correlates of preconvulsive and convulsive doses of chlorinated hydrocarbon insecticides in the CNS. Neuropharmacology 12: 63–76PubMedCrossRefGoogle Scholar
  83. Julien RM, Fowler GW, Danielson MG (1975) The effects of antiepileptic drugs on estrogen-induced electrographic spike-wave discharge. J Pharmacol Exp Ther 193: 647–656PubMedGoogle Scholar
  84. Kibler RF, O’Neill RP, Robin ED (1964) Intracellular acid–base relations of dog brain with reference to the brain extracellular volume. J Clin Invest 43: 431–443PubMedCrossRefGoogle Scholar
  85. Killam EK (1976) Measurement of anticonvulsant activity in the Papio papio model of epilepsy. Fed Proc 35: 2264–2269PubMedGoogle Scholar
  86. King LJ, Carl J (1969) Effects of antiepileptic drugs on brain energy reserves during convulsions. J Neurochem 16: 637–643PubMedCrossRefGoogle Scholar
  87. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA (1978) Antiepileptic drug development. II. Anticonvulsant drug screening. Epilepsia 19: 409–428Google Scholar
  88. Lahan GD, Osuide G., Stansfield F (1979) Anticonvulsant properties of ethyl-N-phtalimidoxy acetate. Br J Pharmacol 67: 441–442Google Scholar
  89. Lemeignan M (1971) Abord pharmacologique de l’etude du mecanisme de Taction convulsivante de l’amino-4 pyridine. Therapie 26: 927–940PubMedGoogle Scholar
  90. Löscher W (1979 a) 3-Mercaptopropionic acid: convulsant properties, effects on enzymes of the γ-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine. Biochem Pharmacol 28:1397–1407Google Scholar
  91. Löscher W (1979 b) A comparative study of the protein binding of anticonvulsant drugs in serum of dog and man. J Pharmacol Exp Ther 208:429–435Google Scholar
  92. Löscher W (1980) Comparative study of the inhibition of GABA aminotransferase by different anticonvulsant drugs. Arch Int Pharmacodyn Ther 243: 48–55PubMedGoogle Scholar
  93. Löscher W, Frey HH (1977) Effect of convulsant and anticonvulsant agents on level and metabolism of γ-aminobutyric acid in mouse brain. Naunyn-Schmiedebergs Arch Pharmacol 296: 263–269PubMedCrossRefGoogle Scholar
  94. Loewe S, Aldous RA, Fox SR, Johnson DG, Perkins W (1955) Isobols of dose-effect relations in the combination of pentylenetetrazole and trimethadione. J Pharmacol Exp Ther 113: 475–480PubMedGoogle Scholar
  95. Lust WD, Kupferberg HJ, Yonekawa WD, Penry JK, Passonneau JV, Wheaton AB (1978) Changes in brain metabolites induced by convulsants or electroshock: effects of anticonvulsant agents. Mol Pharmacol 14: 347–356PubMedGoogle Scholar
  96. McMillen B, Isaac L (1978) Effects of pentylenetetrazol and trimethadione on feline brain monoamine metabolism. Biochem Pharmacol 27: 1815–1820PubMedCrossRefGoogle Scholar
  97. Midha KK, Buttar HS, Rowe M, Dupuis J (1979) Metabolism and disposition of trimethadione in pregnant rats. Epilepsia 20: 417–423PubMedCrossRefGoogle Scholar
  98. Morrell F, Bradley W, Ptashne M (1959) Effect of drugs on discharge characteristics of chronic epileptogenic lesions. Neurology 9: 492–498PubMedGoogle Scholar
  99. Nahorski SR (1972) Biochemical effects of the anticonvulsants trimethadione, ethosuximide and chlordiazepoxide in rat brain. J Neurochem 19: 1937–1946PubMedCrossRefGoogle Scholar
  100. Nakamura K, Bernheim F (1961) Effects of some drugs on the γ-aminobutyric acid transaminase and the succinic semialdehyde dehydrogenase of rat brain. Jpn J Pharmacol 11: 37–45PubMedGoogle Scholar
  101. Nolte H, Von Schnakenburg K (1973) Morphologische und pharmakologisch-toxikologische Aspekte der Hyperoxie. Int J Clin Pharmacol 74: 340–347Google Scholar
  102. Okamoto M, Rosenberg HC, Boisse NR (1977) Evaluation of anticonvulsants in barbiturate withdrawal. J Pharmacol Exp Ther 202: 479–489PubMedGoogle Scholar
  103. Osuide G (1972) Pharmacological properties of amino-oxyacetic acid in the chicken. Br J Pharmacol 44: 31–44PubMedGoogle Scholar
  104. Paton WDM (1967) Experiments on the convulsant and anaesthetic effects of oxygen. Br J Pharmacol 29: 350–366Google Scholar
  105. Poswillo DE (1972) Tridione and paradione as suspected teratogens. Ann R Coll Surg Engl 50: 367–370PubMedGoogle Scholar
  106. Richards RK (1946) Tridione: a new experimental drug for treatment of convulsive and related disorders. I. Pharmacologic aspects. Arch Neurol Psychol 55: 164Google Scholar
  107. Richards RK, Everett GM (1944) Analgesic and anticonvulsive properties of 3,5,5–Google Scholar
  108. Trimethyloxalidine-2,4-dione (tridione). Fed Proc 3:39Google Scholar
  109. Richards RK, Everett GM (1946) Tridione: a new anticonvulsant drug. J Lab Clin Med 31: 1330–1336PubMedGoogle Scholar
  110. Richter W (1964) Estimation of vasodilator drug effects in mice by measurements of paw skin temperature. Acta Pharmacol Toxicol 21: 91–104CrossRefGoogle Scholar
  111. Rifkind AB (1974) Teratogenic effects of trimethadione and dimethadione in the chick embryo. Toxicol Appl Pharmacol 30: 452–457PubMedCrossRefGoogle Scholar
  112. Rifkind AB, Gilette PN, Song CS, Kappas A (1973) Drug stimulation of γ-aminolevulinic acid synthetase and cytochrome P-450 in vivo in chick embryo liver. J Pharmacol Exp Ther 185: 214–225PubMedGoogle Scholar
  113. Rollins DE, Reed DJ (1970) Transport of DMO out of cerebrospinal fluid of rats. Am J Physiol 219: 1200–1204PubMedGoogle Scholar
  114. Roos A (1965) Intracellular pH and intracellular buffering power of the cat brain. Am J Physiol 209: 1233–1246PubMedGoogle Scholar
  115. Rümke CL (1961) Beeinflussung der Krampfwirkung des Bemegrids. Naunyn-Schmiedebergs Arch Exp Pathol Pharmacol 241: 511–512CrossRefGoogle Scholar
  116. Rümke CL (1963) The influence of drugs on the duration of hexobarbital and hydroxydione narcosis in mice. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 244: 519–530PubMedGoogle Scholar
  117. Rümke CL, Bout J (1960) Die Beeinflussung der Hexobarbitalnarkose durch vorher verabfolgte Pharmaka. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 240: 218–223Google Scholar
  118. Sanders HD (1967) A comparison of the convulsant activity of procaine and pentylenetetrazol. Arch Int Pharmacodyn Ther 170: 165–177PubMedGoogle Scholar
  119. Shannon HE, Hotzmann SG (1976) Blockade of the specific lethal effects of narcotic analgesics in the mouse. Eur J Pharmacol 39: 295–303PubMedCrossRefGoogle Scholar
  120. Shull EG, Fabro SE (1978) The teratogenicity of trimethadione in the CD-I mouse. Pharmacologist 20: 263Google Scholar
  121. Singh N, Sinha JN, Rastogi SK, Dua PR, Kohli RP (1971) An experimental investigation on the antiarrhythmic activity of antiepileptic agents. Jpn J Pharmacol 21: 755–761PubMedCrossRefGoogle Scholar
  122. Snead OC, Bearden LJ (1980) Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucin encephalin. Science 210: 1031–1033PubMedCrossRefGoogle Scholar
  123. Snead III OC, Bearden LJ, Pegram V (1980) Effect of acute and chronic anticonvulsant administration on endogenous γ-hydroxybutyrate in rat brain. Neuropharmacology 19: 47–52PubMedCrossRefGoogle Scholar
  124. St-Laurent J (1971) Effect of trimethadione on the self-stimulation phenomenon. Can J Physiol Pharmacol 49: 850–853 (1971)Google Scholar
  125. Steinhauer HB, Anhut H, Hertting G (1979) The synthesis of prostaglandins and thromboxane in the mouse brain in vivo. Naunyn-Schmiedebergs Arch Pharmacol 310: 53–58PubMedCrossRefGoogle Scholar
  126. Stone WE, Javid MJ (1979) Quantitative evaluation of the actions of anticonvulsants against different chemical convulsants. Arch Int Pharmacodyn Ther 240: 66–78PubMedGoogle Scholar
  127. Stone WE, Javid MJ (1980) Effects of anticonvulsants and glutamate antagonists on the convulsive action of kainic acid. Arch Int Pharmacodyn Ther 243: 56–65PubMedGoogle Scholar
  128. Struck HC, Stumpff DL, Caffrey RJ (1950) Effect of tridione (3,3,5-trimethyl oxazolidine-2,4-dione) on the oxygen uptake of motor and sensory cortex of dog brain. Fed Proc 9: 123Google Scholar
  129. Swinyard EA (1949) Laboratory assay of clinically effective antiepileptic drugs. J Am Pharm Ass Sci Ed 38: 201–204CrossRefGoogle Scholar
  130. Swinyard EA (1969) Laboratory evaluation of antiepileptic drugs. Epilepsia 10: 107–119PubMedCrossRefGoogle Scholar
  131. Swinyard EA, Castellion AW (1966) Anticonvulsant properties of some benzodiazepines. J Pharmacol Exp Ther 151: 369–375PubMedGoogle Scholar
  132. Swinyard EA, Brown WC, Goodman LS (1952 a) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106: 319–330Google Scholar
  133. Swinyard EA, Schiffman DO, Goodman LS (1952 b) Effects of liver injury and nephrectomy on the anticonvulsant activity of oxazolidine-2,4-diones. J Pharmacol Exp Ther 105: 365–370Google Scholar
  134. Swinyard EA, Madsen J A, Goodman LS (1954) The effect of β-diethylaminoethyldiphenyl-propylacetate (SKF No. 525 A) on the anticonvulsant properties of antiepileptic drugs. J Pharmacol Exp Ther 111: 54–63PubMedGoogle Scholar
  135. Swinyard EA, Castellion AW, Fink GB, Goodman LS (1963) Some neurophysiological and neuropharmacological characteristics of audiogenic-seizure-susceptible mice. J Pharmacol Exp Ther 140: 375–384PubMedGoogle Scholar
  136. Taylor JD, Bertcher EL (1952) The determination and distribution of trimethadione ( Tridione) in animal tissues. J Pharmacol Exp Ther 106: 277–285Google Scholar
  137. Taylor JD, Richards RK, Everett GM, Bertcher EL (1950) Effect of tridione (3,3,5-trimethyloxazolidine-2,4-dione) on the oxygen uptake of mouse brain. J Pharmacol Exp Ther 98: 392–399PubMedGoogle Scholar
  138. Taylor JD, Davin JC, Richards RK (1956) Duration of anticonvulsant action of trimetha-dione and some demethylated oxazolidinediones against pentylenetetrazol in mice. Fed Proc 15: 491Google Scholar
  139. Thueson DO, Withrow CD, Giam CS, Woodbury DM (1974) Uptake, distribution, me–tabolism, and excretion of trimethadione in rats. Epilepsia 15: 563–578PubMedCrossRefGoogle Scholar
  140. Toman JEP (1949) The neuropharmacology of antiepileptics. Electroencephalogr Clin Neurophysiol 1: 33–44PubMedGoogle Scholar
  141. Toman JEP, Goodman LS (1948) Anticonvulsants. Physiol Rev 28: 409–432PubMedGoogle Scholar
  142. Torda C, Wolff HG (1947) Effect of convulsant and anticonvulsant agents on acetylcholine metabolism (activity of choline acetylase, cholinesterase) and on sensitivity to acetylcholine of effector organs. Am J Physiol 151: 345–354PubMedGoogle Scholar
  143. Torda C, Wolff HG (1950) Effect of convulsant and anticonvulsant agents on the activity of cytochrome oxidase. Proc Soc Exp Biol Med 74: 744–746PubMedGoogle Scholar
  144. Ueki S, Araki Y, Watanabe S (1977) Changes in sensitivity of mice to anticonvulsant drugs following bilateral olfactory bulb ablations. Jpn J Pharmacol 27: 183–192PubMedCrossRefGoogle Scholar
  145. Waddell WJ, Butler TC (1957) Renal excretion of 5,5-dimethyl-2,4-oxazolidinedione (product of demethylation of trimethadione). Proc Soc Exp Biol Med 96: 563–565PubMedGoogle Scholar
  146. Wallin RF, Blackburn WH, Napoli MD (1970) Pharmacologic interactions of albutoin with other anticonvulsant drugs. J Pharmacol Exp Ther 174: 276–282PubMedGoogle Scholar
  147. Weaver LC, Swinyard EA, Goodman LS (1958) Anticonvulsant drug combinations: diphe-nylhydantoin combined with other antiepileptics. J Am Pharm Assoc Sci Ed 47: 645–648CrossRefGoogle Scholar
  148. Wilkison DM, Halpern LM (1974) Effects of selected anticonvulsants on conjugated estrogen–induced epileptiform activity. Proc West Pharmacol Soc 17: 87–91Google Scholar
  149. Withrow CD (1980) Oxazolidinediones. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic drugs: mechanism of action. Raven, New York, pp 577–586Google Scholar
  150. Withrow CD (1982) Trimethadione: absorption, distribution and excretion. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic drugs. Raven, New York, pp 681–687Google Scholar
  151. Withrow CD, Stout RJ, Barton LJ, Beacham WS, Woodbury DM (1968) Anticonvulsant effects of 5,5-dimethyl-2,4-oxazolidinedione ( DMO ). J Pharmacol Exp Ther 161: 335–341Google Scholar
  152. Woodbury DM (1952) Effects of chronic administration of anticonvulsant drugs, alone and in combination with desoxycorticosterone, on electroshock seizure threshold and tissue electrolytes. J Pharmacol Exp Ther 105: 46–57PubMedGoogle Scholar
  153. Woodbury DM, Rollins LT, Gardner MD, Hirschi WL, Hogan JR, Rallison ML, Tanner GS, Brodie DA (1958) Effects of carbon dioxide on brain excitability and electrolytes. Am J Physiol 192: 79–90PubMedGoogle Scholar
  154. Woodbury DM, Penry JK, Schmidt RP (eds) (1972) Antiepileptic drugs. Raven, New YorkGoogle Scholar
  155. Woodbury DM, Penry JK, Pippenger CE (eds) (1982) Antiepileptic drugs. Raven, New YorkGoogle Scholar
  156. Yen HCY, Silverman AJ, Salvatore A (1960) Iproniazid reinforcement of anticonvulsants. Fed Proc 19: 278Google Scholar
  157. Yen HCY, Salvatore AT, Silverman AJ, King TO (1962) A study of the effect of iponiazid on anticonvulsants in mice. Arch Int Pharmacodyn Ther 140: 631–645PubMedGoogle Scholar
  158. Yeoh PN, Wolf HH (1970) Pharmacological evaluation of seizures induced by electrical stimulation of the hippocampus. J Pharm Sci 59: 950–954PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • R. Kretzschmar
  • H. J. Teschendorf

There are no affiliations available

Personalised recommendations